379MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Updated results from BEGONIA, a phase Ib/II study

Peter Schmid, Piotr J. Wysocki, X. Cynthia, Y.H. Park, Renan Fernandes, Simon Lord, Richard D. Baird, Catherine Prady, Kyung Hae Jung, Jamil Asselah, Robert Huisden, Ross Stewart, K. Heider, Petra Vuković, Neelima Denduluri, Zbigniew Nowecki